Objective: To outline the role of a new drug, tolvaptan, in treating severe and chronic hyponatraemia. Tolvaptan decreases aquaporin expression in renal collecting ducts, by inhibiting antidiuretic hormone (ADH)-V2 receptors, to promote free water clearance. Given its mechanism of action, this drug seems the ideal treatment for the syndrome of inappropriate antidiuretic hormone secretion (SIADH) when the osmotic imbalance leads to life threatening complications. Data sources: A case is described of severe hyponatraemia deriving from SIADH secondary to meningoencephalitis in a patient admitted to hospital for traumatic brain injury. Data extraction: Clinical, laboratory and radiological data at presentation and for a 1 year of follow-up were analysed. Data synthesis: Tolvaptan ameliorated hyponatraemia, brain oedema and consciousness, and drug withdrawal led to recurrence of hyponatraemia and coma. Conclusions: In patients with SIADH, which is not self-limited, and is associated with severe cognitive impairment, the use Tolvaptan may prove life saving and should be rigorously evaluated.

Syndrome of inappropriate secretion of antidiuretic hormone in traumatic brain injury: When tolvaptan becomes a life saving drug / G. Graziani, D. Cucchiari, A. Aroldi, C. Angelini, P. Gaetani, C. Selmi. - In: JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY. - ISSN 0022-3050. - 83:5(2012), pp. 510-512.

Syndrome of inappropriate secretion of antidiuretic hormone in traumatic brain injury: When tolvaptan becomes a life saving drug

D. Cucchiari;C. Selmi
2012

Abstract

Objective: To outline the role of a new drug, tolvaptan, in treating severe and chronic hyponatraemia. Tolvaptan decreases aquaporin expression in renal collecting ducts, by inhibiting antidiuretic hormone (ADH)-V2 receptors, to promote free water clearance. Given its mechanism of action, this drug seems the ideal treatment for the syndrome of inappropriate antidiuretic hormone secretion (SIADH) when the osmotic imbalance leads to life threatening complications. Data sources: A case is described of severe hyponatraemia deriving from SIADH secondary to meningoencephalitis in a patient admitted to hospital for traumatic brain injury. Data extraction: Clinical, laboratory and radiological data at presentation and for a 1 year of follow-up were analysed. Data synthesis: Tolvaptan ameliorated hyponatraemia, brain oedema and consciousness, and drug withdrawal led to recurrence of hyponatraemia and coma. Conclusions: In patients with SIADH, which is not self-limited, and is associated with severe cognitive impairment, the use Tolvaptan may prove life saving and should be rigorously evaluated.
Benzazepines; Brain Injuries; Humans; Inappropriate ADH Syndrome; Male; Meningoencephalitis; Middle Aged; Antidiuretic Hormone Receptor Antagonists; Neurology (clinical); Psychiatry and Mental Health; Surgery; Arts and Humanities (miscellaneous)
Settore MED/04 - Patologia Generale
http://jnnp.bmj.com/content/83/5/510.full.pdf+html
Article (author)
File in questo prodotto:
File Dimensione Formato  
510.full.pdf

accesso riservato

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 122.86 kB
Formato Adobe PDF
122.86 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/252383
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 13
social impact